Russia’s veterinary pharmaceutical market has undergone a remarkable transformation. In just a few years, it has shifted from 70% import dependence to domestic products dominating the market. The sector grew 11% in 2025 to reach 134.6 billion rubles, with projections of 178.6 billion rubles by 2030. Behind this growth lies a story of accelerated import substitution, massive state support, and a determined push toward technological self-sufficiency in animal health.
Market Size and Structure
The Russian veterinary products market reached 134.6 billion rubles in 2025, an 11% increase over 2024. According to Timur Chibilyaev, executive director of the National Veterinary Association, the market is projected to grow by approximately one third by 2030, reaching 178.6 billion rubles.
Chemical-pharmaceutical preparations account for 73% of sales (98.3 billion rubles), while immunobiological products represent 27% (36.3 billion rubles). The market is heavily oriented toward agricultural animals, which account for 65% of the total, with companion animals making up the remaining 35%.
Poultry farming is the dominant consumer segment, accounting for approximately 45% of all veterinary drug use and two-thirds of vaccine production. The swine sector consumes about a quarter of vaccine volumes, with cattle and other species accounting for the remainder.
The Import Substitution Success
The most dramatic shift in Russia’s veterinary industry has been the reversal of import dependence. Before 2022, foreign products controlled roughly 70% of the Russian market. By 2025, domestic products represented 72.4% of vaccine packages and 79% of chemical-pharmaceutical preparations. In value terms, the retail market saw domestic products reach 56% share in 2025, climbing to 59% by January 2026.
The retail segment has been particularly dynamic. According to RNC Pharma data, the Russian retail veterinary medicine market grew 17.7% in 2025 to reach 49.2 billion rubles, with volume growth of 13.2% to 276.8 million minimum dosage units. Domestic products drove this growth, with sales increasing 37% in rubles and 26% in units, while the import segment stagnated at -0.2% in rubles and declined 11.3% in physical volume.
Vaccine Production: A Regional Powerhouse
Russia’s veterinary vaccine production has expanded significantly. Between 2017 and 2024, the sector showed a compound annual growth rate of 9.7%, with output reaching 30.5 billion doses in 2025—more than double the 2017 figure.
The Northwestern Federal District leads vaccine production with 59.7% of the total, home to major producers like NPP Avivak, which specializes in poultry vaccines. The Central Federal District follows with 38.9%, hosting the Shchelkovo Biocombinat, the Federal Center for Animal Health (VNIIZZh), and other key enterprises.
Regional dynamics shifted in 2025: the Northwestern district increased production by 2.4% to 18.2 billion doses, while the Central district saw a 14.6% decline to 11.9 billion doses. The North Caucasus district recorded the strongest growth at 32.6%.
State Support and Regulatory Reform
The transformation of Russia’s veterinary industry has been driven by deliberate government policy. A March 2022 decree reduced the registration period for domestic veterinary drugs from 160 to 60 days, dramatically accelerating market entry. In 2025 alone, 130 new veterinary drugs were registered, of which 101 (77.7%) were domestic developments.
The federal project “Veterinary Drugs” (part of the national project “Technological Support for Food Security”) allocated 5 billion rubles for the creation of new drugs and vaccines, with an additional 1 billion rubles in production subsidies starting in 2026. The project sets ambitious targets: increasing the livestock sector’s vaccine self-sufficiency from 49% to 61% and expanding vaccine production from 18.6 to 20.3 billion doses by 2030.
A landmark development came on March 30, 2026, when President Putin signed a decree creating the “Russian Biological Industrial Company,” consolidating five federal state biofactories: Shchelkovo Biocombinat, Armavir Biofactory, Kursk Biofactory, Oryol Biofactory, and Stavropol Biofactory. The consolidated entity aims to more than double vaccine and diagnostic production by 2030, focusing on swine, poultry, and cattle.
Leading Producers and Market Players
The Russian veterinary pharmaceutical sector includes approximately 100 companies, typically high-tech operations with small workforces and specialized production. Key domestic manufacturers include:
- Vetbiokhim: A major producer of companion animal vaccines, with 15 immunobiological products for dogs and cats. The company produced over 4 million doses in the first half of 2025, a 47% increase year-on-year, and has invested in a new production line.
- VNIIZZh (Federal Center for Animal Health): Registered seven new vaccines in 2025 covering poultry, fish, cattle, rabbits, and carnivores, including vaccines against avian influenza and Newcastle disease.
- Shchelkovo Biocombinat: Has produced 12 vaccines over the past five years and increased output 3.6-fold. The enterprise is developing over 10 additional vaccines and is positioning itself for “import-ahead” rather than just import substitution, using technologies not yet applied in practice.
- Ekoprom: The second-largest player in retail with a 9.4% market share, followed by AgroVetZashchita at 8.3% and Vetbiokhim at 7.5%.
Despite the domestic surge, the American company Zoetis retains the top position in retail sales with 13.6% of the market as of mid-2026, followed by Russia’s Ekoprom (9.4%) and Slovenia’s KRKA (9.1%).
Retail Market Dynamics and Online Channels
The retail veterinary medicine market is increasingly shaped by digital channels. In Q1 2026, online sales reached 33.5% of market value and 29.4% of unit sales, up from below 30% and 21.9% respectively a year earlier. During the March seasonal peak, online sales exceeded 37% of market value.
Demand is led by ectoparasite medicines and vaccines. In value terms, Zoetis’s Simparica ranked first with over 10% of the market, followed by Bravecto at 5.4% and Tixfly at 4.9%. In unit terms, the domestic Tixfly (Vetfarmstandart) outperformed Bravecto, selling 290,700 minimum dosage units compared with 254,400. The domestic vaccine MultiCan (Vetbiokhim) captured leadership in dog vaccination in January 2026.
Regional concentration remains significant: Moscow, Moscow Region, and Krasnodar Territory together generate over 31% of total veterinary medicine spending, with Moscow alone accounting for around 15%.
Challenges and Outlook
Despite impressive progress, challenges remain. The sector must continue closing the gap in high-tech segments, particularly for complex immunobiological products and innovative pharmaceuticals. The consolidation of state biofactories under the Russian Biological Industrial Company represents an attempt to consolidate research and production competencies to accelerate development.
The federal project’s targets through 2030 include achieving 70% self-sufficiency in chemical-pharmaceutical veterinary preparations and full import substitution of critically important drugs and vaccines. With continued state support, accelerated registration pathways, and growing domestic manufacturing capacity, Russia’s veterinary industry appears positioned to achieve these goals—though the ultimate test will be whether it can transition from import substitution to genuine technological leadership.
